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of Life (QoL) of children and adolescents with ADHD.
METHODS: ADORE, a 2-year, prospective, observational study
in Attention Deﬁcit/ Hyperactivity Disorder (ADHD) enrolling
patients across 10 European countries. ADORE main objective
is to describe the relationship between treatment prescribed and
QoL of ADHD, in actual practice, over a two-year period.
Patients were enrolled if in the opinion of the investigator
showed hyperactive/ inattentive/ impulsive symptoms. QoL was
measured with the Child Health and Illness Proﬁle (CHIP-CE).
Clinical ADHD speciﬁc and generic outcomes were measured
with ADHD-RS, CGI-Severity, SDQ, and CGAS. Other out-
comes included parent’s health problems, truancy, and social
invites. Treatments were classiﬁed as pharmacotherapy, psy-
chotherapy, pharmacotherapy and psychotherapy combination,
other, and none. All results presented are descriptive. Percentages
were calculated based on the number of patients who answered
the question of interest. RESULTS: A total of 1478 eligible
patients were analysed. Overall mean age (sd) for patients was
9.0 years (2.5), 84% of them being male. At baseline, 270
patients (19%) were prescribed psychotherapy, 360 (25%) phar-
macotherapy, 356 (25%) pharmacotherapy and psychotherapy
combination, 148 (10%) other therapy, and 294 (21%) nothing.
At 3 months, nearly 70% of the patients were receiving either
pharmacotherapy (442 [40.0%]) or its combination with psy-
chotherapy (310 [28.1%]). Baseline mean CGI-Severity score
(SD) was 4.4 (0.9) for the overall group with no major differ-
ences between the treatment regimens. At 3 months, the biggest
improvement was seen in the patients receiving pharmacother-
apy (−1.3 [1.1]) followed by combination (−1.1 [1.1]). Results
were consistent across scales (ADHD-RS, SDQ, CGAS, CHIP-
CE). CONCLUSIONS: Presented information suggests that, on
average, patient’s receiving pharmacotherapy or its combination
with psychotherapy experienced greater improvements over the
ﬁrst three months in the study.
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OBJECTIVES: The aim of this study was to evaluate the survival
of patients initiating hemodialysis (HD), and to analyze whether
low Health-Related Quality of Life (HRQoL) levels are predic-
tors of mortality in the short term, controlling certain variables
that had been shown in other studies to have a bearing on sur-
vival, and using scores, standardized for age and sex, of the
HRQoL measurement tool employed. METHODS: A multicen-
tric prospective study of all patients on HD in all the dialysis
units in Asturias, a region with a little over one million inhabi-
tants, from the 1st of January 2001 to the 30th September 2002.
A total of 199 patients initiated HD in our region and survived
the ﬁrst 3 months. A total of 137 patients who remained in HD
for at least three months had complete responses on HRQoL
measures, those that had received a transplant during the follow-
up were censored to survival analysis. RESULTS: It was observed
adjusted relative risk (RR) of death increased by 5% for each
year age increased; RR = 1.05 (CI 95% 1.01 1.09): p = 0.006,
in the same way that for each point that MCS increased, the
adjusted RR of death diminished 4%; RR = 0.96 (CI 95% 0.94
0.99); p = 0.006. CONCLUSIONS: Mental health has been
shown to be a factor independently associated with mortality; as
the MCS score worsens the adjusted relative risk of death of a
patient in HD increases.
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In routine clinical care, ADHD is rarely diagnosed in the adult
population in Germany. Little is known about actual care for
adult outpatients. To date, no pharmaceutical product has been
licensed in Germany for use in adult ADHD. OBJECTIVE: To
assess the (off-label) use of methylphenidate in this group of
patients, using the comprehensive medical claims database of
Nordbaden/Germany, covering an insured population of 2.234
m (or 2.7% of the German population), and hereof 1.766 m
adults, in 2003. METHODS: 630 adults with a diagnosis of
ADHD (ICD-10-codes F90.0, F90.1, “Hyperkinetic Disorder”)
were identiﬁed (administrative prevalence: 0.04%). For a retro-
spective analysis of methylphenidate prescriptions by gender and
coexisting conduct disorder, data from the organization of
licensed physicians (Kassenaerztliche Vereinigung) in Nord-
baden/Germany were combined with data from the regional
vdak, an association of statutory sick funds. RESULTS: One
third (34.6%) of adult patients with ADHD were treated (off-
label) with methylphenidate. Treatment prevalence was some-
what higher for males (39.4%, 95%-CI 31.3%–48.0%; cf.
females, 29.0%, 21.2%–37.9%). Patients with pure Hyperki-
netic Disorder (F90.0) appeared to be more likely (36.8%,
30.7%–43.3%) than patients with concomitant conduct 
disorder (F90.1: 14.8%, 4.2%–33.7%) to receive medication
(methylphenidate). Most methylphenidate prescriptions for adult
patients were written by psychiatrists and other mental health
care specialists (50% of DDDs) and by general practitioners
(31%). Adult patients accounted for 9% of the total number of
methylphenidate prescriptions for patients with ADHD in Nord-
baden. CONCLUSIONS: Besides the low administrative preva-
lence of adult ADHD in Nordbaden, the relatively higher
medication rate of patients without concomitant conduct disor-
der constitutes a peculiar difference compared to prescribing pat-
terns observed for children and adolescents. Though currently
the budgetary impact of adult ADHD seems moderate, this is
likely to change when physicians begin to recognize adult ADHD
more frequently, and once drugs for treatment of the condition
will have been licensed.
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OBJECTIVES: A budget impact model was used to estimate the
effect of introducing ziprasidone on acute bipolar mania drug-
related costs in Spain. METHODS: The model is based on
disease prevalence, incidence, drug use, adverse effects, drug
acquisition cost and sales forecasting data speciﬁc to Spain. It
takes the perspective of the Spanish National Pharmaceutical
budget and has a time horizon of 3 years. Drugs considered in
the study were lithium, valproate, olanzapine, risperidone, que-
tiapine, aripiprazole, haloperidol, lamotrigine, oxcarbazepine
and topiromate. Market shares for ziprasidone for the upcom-
ing three years were estimated at 9%, 14% and 17%. RESULTS:
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Target population in Spain is estimated at 500,000 patients and
15% of those receive a monoterapia drug treatment for acute
bipolar mania. Nowadays, when considering drug costs, direct
medical costs and adverse events treatment, average annual cost
per treated patient in Spain is estimated at €4006 and it is likely
to be estimated at €4039 after the introduction of ziprasidone.
Sensibility analysis showed that at a constant market share of
24% for the forecasted three years, then the introduction of
ziprasidone is not likely to have any economic impact on the
Spanish National Pharmaceutical budget. CONCLUSIONS:
This budget impact model shows that the introduction of ziprasi-
done is likely to have minimal impact on acute bipolar mania
medication costs in Spain. Current drug costs due to acute
bipolar mania were estimated at €908 millions for the next 3
years and at €916 millions after the introduction of ziprasidone.
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ADHD is a common disorder of childhood and adolescence in
the US and Europe. The NIMH MTA Study is a clinical land-
mark trial, including 579 children age 7–9.9 years with ADHD
according to DSM-IV criteria, who were randomly assigned to
14 months of medication management (MedMgt), intense behav-
ioral treatment (Beh), both combined (Comb), or community care
(CC). OBJECTIVE: To evaluate the cost-effectiveness of clinically
proven treatment strategies (neither placebo nor single drugs) for
ADHD and Hyperkinetic Disorder (HKD/HKCD, a subgroup
meeting ICD-10-based diagnostic criteria used in Europe) in ﬁve
countries, using patient-level data from the MTA Study over 14
months. METHODS: Medical resource utilization data came
from the MTA, excluding its research component. Unit costs (year
2005) were calculated from a societal and from a third-party
payer’s perspective for Germany, The Netherlands, Sweden, UK,
and USA. Corresponding to the primary study endpoint, treat-
ment response was deﬁned as normalization of core symptoms
(SNAP-IV teacher/parent scores <1). Utility estimates were
derived from expert estimates and parent-proxy-ratings.
RESULTS: Incremental cost-effectiveness ratios (ICERs) were
determined for the total study population and subgroups with
pure ADHD (without comorbidity, n = 184), pure HKD (n = 77),
or HKD/HKCD (n = 145). ICERs per additional patient “nor-
malized” ranged from to dominance to €4200 for MedMgt versus
CC and from €21,000 to €100,000 for Comb versus MedMgt.
MedMgt dominated Beh and exhibited extended dominance over
CC compared to a hypothetical “Do Nothing” alternative.
Results were supported by cost-effectiveness acceptability and
sensitivity analyses. CONCLUSIONS: Despite international dif-
ferences regarding standards of care, diagnostic criteria, and unit
costs, key ﬁndings for European jurisdictions were consistent with
US results. Although cost-utility estimates for this pediatric pop-
ulation should be interpreted with caution, results indicate accept-
able to attractive cost-effectiveness of an intense MedMgt
strategy. Further analyses will have to explore the impact of psy-
chiatric comorbidity and broader clinical endpoints.
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Beyond disease-deﬁning core symptoms of inattention, hyperac-
tivity, and impulsivity, ADHD is characterized by functional
impairment of patients. The Columbia Impairment Scale (CIS) is
a parent rating scale with relatively strong psychometric prop-
erties, tapping four major dimensions: interpersonal relations,
psychopathology, schoolwork, and use of leisure time. OBJEC-
TIVES: CIS ratings from the NIMH MTA Study (n = 579 chil-
dren with ADHD according to DSM-IV-criteria) were used as an
alternative outcome measure to evaluate the cost-effectiveness of
medication management (MedMgt), intense behavioral treat-
ment (Beh), both combined (Comb), or community care (CC) in
the study population and in three subgroups: hyperkinetic dis-
order (according to ICD-10-criteria preferred in Europe); pure
HKD or HKD/HKCD, and in pure ADHD, over 14 months.
METHODS: For costing (societal and third-party payer’s per-
spectives), patient-level resource utilization data were combined
with country-speciﬁc unit costs for Germany, The Netherlands,
Sweden, UK, and United States (year 2005). Incremental cost-
effectiveness ratios (ICERs) were determined using functional
improvement (CIS effect size [ES], Cohen’s d) as clinical outcome
criterion. Four treatment strategies and a hypothetical “Do
Nothing” alternative were compared with each other. RESULTS:
The four MTA treatment strategies were all clinically effective.
Across jurisdictions, both CC versus “Do Nothing” (ICERs
ranging from €1200/ES to €2600/ES) and MedMgt (ICERs
versus “Do Nothing” from €1000/ES to €2700/ES, ICERs versus
CC from dominance to €3000/ES) appeared attractive on
grounds of cost-effectiveness. MedMgt dominated Beh, and
ICERs for Comb versus MedMgt ranged from €500,000/ES to
€1,000,000/ES. Results for subgroups with pure ADHD,
HKD/HKCD, and pure HKD were broadly similar. Sensitivity
analyses including probabilistic evaluations using non-paramet-
ric bootstrapping supported these ﬁndings. CONCLUSIONS:
Despite notable international differences in terms of diagnostic
criteria, standards of care, and unit costs, the cost-effectiveness
of MTA-based clinical treatment strategies for patients with pure
ADHD seemed remarkably similar across jurisdictions. The
impact of comorbidity remains to be explored.
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OBJECTIVE: In light of recent clinical evidence, the indication
of the NMDA antagonist memantine has been extended to
“moderate to severe Alzheimer’s disease (AD)”. No pharmaco-
economic evaluation has been performed in this indication to
